MIST is a multimodal survival prediction framework that fuses whole-slide images and genomic profiles by representing genomic features as tokens that query histology context tokens derived from a foundation model. The architecture enriches molecular information with histology context before survival prediction, avoiding late-stage merging of separately encoded modalities. Training incorporates discrete-time survival prediction, genomic feature masking, WSI dropout, and contrastive alignment, and demonstrates improved external C-index across colon, renal, lung, and glioblastoma cohorts compared to standard fusion baselines.
arXiv:2510.06113v2 Announce Type: replace Abstract: Survival analysis plays a vital role in making clinical decisions. However, the models currently in use are often difficult to interpret, which red...
arXiv:2607. 16260v1 Announce Type: cross Abstract: Multimodal survival analysis utilizing whole slide images (WSIs) and genomic profiles is fundamental for cancer prognosis.
arXiv:2606. 29949v1 Announce Type: cross Abstract: H&E-stained whole-slide images offer cohort-scale availability and rich spatial context but lack molecular specificity, whereas bulk RNA-seq provides transcriptome-wide resolution at high cost with limited archival availability.
Accurate prognosis prediction is important for treatment planning in lung cancer, but deep learning-driven survival modelling is often limited by the scarcity of curated imaging cohorts with reliable outcome data. This study evaluates whether representations from a domain-specific foundation model can be used for multimodal survival prediction in data-constrained clinical settings.
arXiv:2606. 15038v1 Announce Type: new Abstract: Accurate time-to-event (TTE) prediction from multimodal clinical data remains challenging due to modality imbalance and distribution shift.
arXiv:2606. 17115v1 Announce Type: cross Abstract: Foundation models (FMs) have emerged as powerful representation extractors for medical data, yet their generalizability to datasets under distribution shift remains underexplored.
The paper presents a newly curated, multi-center, multi-modal, and longitudinal lung cancer dataset comprising 1,365 patients with whole-slide images, CT scans, PET scans, structured clinical data, transcriptomics, and follow-up information. The dataset features substantial, non-uniform missingness across modalities, making it ideal for evaluating robust multi-modal fusion strategies. Benchmarks on 12‑month overall survival, disease‑specific survival, and longitudinal hazard prediction demonstrate that integrating complementary modalities consistently outperforms uni-modal approaches, even under severe missing data.
arXiv:2607. 07725v1 Announce Type: cross Abstract: Genomic prediction models often fail to transfer across institutions because sequencing panels differ across sites, creating structural feature missingness at deployment.
SCOUT is a concept‑grounded multimodal transformer that generates whole‑slide pathology reports by integrating local histological patterns, whole‑slide context, and expert‑curated diagnostic concepts. It uses evolving visual representations and recursively updated slide‑ and concept‑conditioned representations, with separate attention pathways during decoding that are fused adaptively for each token. Evaluated on TCGA‑BRCA, HistAI, and REG‑2025, SCOUT outperformed existing methods, improving BLEU, METEOR, and ROUGE‑L scores and raising the Clinical Report Quality Score on REG‑2025.
arXiv:2609.14072v1 Announce Type: new Abstract: Large Language Models (LLMs) have displayed impressive capabilities in handling tasks that require few demonstration examples, making them effective fe...
arXiv:2605. 25050v2 Announce Type: replace-cross Abstract: Integrating multimodal datasets in clinical oncology is frequently hindered by high dimensionality and blockwise missingness, where entire data sources are unavailable for specific patient subsets.
arXiv:2410. 00945v2 Announce Type: replace-cross Abstract: Gene-expression profiling is widely used in research and central to many areas of precision oncology, but remains costly and not universally accessible.